TY - JOUR
T1 - Long-term outcomes following successful endoscopic treatment of T1 esophageal adenocarcinoma
T2 - a multicenter cohort study
AU - Kahn, Allon
AU - Song, Kevin
AU - Dhaliwal, Lovekirat
AU - Thanawala, Shivani
AU - Hagen, Catherine E.
AU - Agarwal, Siddharth
AU - McDonald, Nicholas M.
AU - Gabre, Joel T.
AU - Falk, Gary W.
AU - Ginsberg, Gregory G.
AU - Wolfsen, Herbert C.
AU - Ramirez, Francisco C.
AU - Leggett, Cadman L.
AU - Wang, Kenneth K.
AU - Iyer, Prasad G.
N1 - Publisher Copyright:
© 2023 American Society for Gastrointestinal Endoscopy
PY - 2023/11
Y1 - 2023/11
N2 - Background and Aims: Endoscopic eradication therapy (EET) is guideline endorsed for management of early-stage (T1) esophageal adenocarcinoma (EAC). Patients with baseline high-grade dysplasia (HGD) and EAC are at highest risk of recurrence after successful EET, but limited data exist on long-term (>5 year) recurrence outcomes. Our aim was to assess the incidence and predictors of long-term recurrence in a multicenter cohort of patients with T1 EAC treated with EET. Methods: Patients with T1 EAC achieving successful endoscopic cancer eradication with a minimum of 5 years’ clinical follow-up were included. The primary outcome was neoplastic recurrence, defined as dysplasia or EAC, and it was characterized as early (<2 years), intermediate (2-5 years), or late (>5 years). Predictors of recurrence were assessed by time to event analysis. Results: A total of 84 T1 EAC patients (75 T1a, 9 T1b) with a median 9.1 years (range, 5.1-18.3 years) of follow-up were included. The overall incidence of neoplastic recurrence was 2.0 per 100 person-years of follow-up. Seven recurrences (3 dysplasia, 4 EAC) occurred after 5 years of EAC remission. Overall, 88% of recurrences were treated successfully endoscopically. EAC recurrence-related mortality occurred in 3 patients at a median of 5.2 years from EAC remission. Complete eradication of intestinal metaplasia was independently associated with reduced recurrence (hazard ratio, .13). Conclusions: Following successful EET of T1 EAC, neoplastic recurrence occurred after 5 years in 8.3% of cases. Careful long-term surveillance should be continued in this patient population. Complete eradication of intestinal metaplasia should be the therapeutic end point for EET.
AB - Background and Aims: Endoscopic eradication therapy (EET) is guideline endorsed for management of early-stage (T1) esophageal adenocarcinoma (EAC). Patients with baseline high-grade dysplasia (HGD) and EAC are at highest risk of recurrence after successful EET, but limited data exist on long-term (>5 year) recurrence outcomes. Our aim was to assess the incidence and predictors of long-term recurrence in a multicenter cohort of patients with T1 EAC treated with EET. Methods: Patients with T1 EAC achieving successful endoscopic cancer eradication with a minimum of 5 years’ clinical follow-up were included. The primary outcome was neoplastic recurrence, defined as dysplasia or EAC, and it was characterized as early (<2 years), intermediate (2-5 years), or late (>5 years). Predictors of recurrence were assessed by time to event analysis. Results: A total of 84 T1 EAC patients (75 T1a, 9 T1b) with a median 9.1 years (range, 5.1-18.3 years) of follow-up were included. The overall incidence of neoplastic recurrence was 2.0 per 100 person-years of follow-up. Seven recurrences (3 dysplasia, 4 EAC) occurred after 5 years of EAC remission. Overall, 88% of recurrences were treated successfully endoscopically. EAC recurrence-related mortality occurred in 3 patients at a median of 5.2 years from EAC remission. Complete eradication of intestinal metaplasia was independently associated with reduced recurrence (hazard ratio, .13). Conclusions: Following successful EET of T1 EAC, neoplastic recurrence occurred after 5 years in 8.3% of cases. Careful long-term surveillance should be continued in this patient population. Complete eradication of intestinal metaplasia should be the therapeutic end point for EET.
UR - http://www.scopus.com/inward/record.url?scp=85173131168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173131168&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2023.06.012
DO - 10.1016/j.gie.2023.06.012
M3 - Article
C2 - 37356631
AN - SCOPUS:85173131168
SN - 0016-5107
VL - 98
SP - 713
EP - 721
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 5
ER -